Tamoxifen (TAM), a selective oestrogen receptor modulator, is one of the most used treatments in oestrogen receptor-positive (ER+) early and metastatic breast cancer (BC) patients. The response to TAM
To facilitate reuse and reproducibility, we provide all 499 simulated datasets generated in this study together with their ground-truth annotations. For each simulation, we release (i) the cell